PharmacoEconomics & Outcomes News

, Volume 781, Issue 1, pp 23–23 | Cite as

Liraglutide cost-effective option for type 2 DM in Italy

Clinical study
  • 12 Downloads

Reference

  1. Hunt B, et al. Long-Term Cost-Effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Clinical Therapeutics : 16 Jun 2017. Available from: URL: http://doi.org/10.1016/j.clinthera.2017.05.354

Copyright information

© Springer International Publishing AG  2017

Personalised recommendations